Testing pathological cargo export as a therapeutic entry point.
Lumenais Bio is an early-stage neuroscience therapeutics venture focused on PSP and related tauopathies. The first program tests whether seed-competent tau export can be reduced through DNAJC5/MAPS cargo-gatekeeping while preserving neuronal proteostasis.
Current posture
Hypothesis-forward, IP-filed, and designed around decisive validation rather than premature claims.
First indication
PSP as the validation beachhead
A severe 4R tauopathy with no approved disease-modifying therapy creates a focused first gate for a tau-export hypothesis.
Intervention layer
Cargo-export gatekeeping
The program tests whether seed-competent tau export can be reduced before extracellular propagation becomes the dominant problem.
Target lane
DNAJC5/MAPS to validate
DNAJC5/MAPS is treated as the first testable cargo-gatekeeping lane, not as completed target validation.
Validation architecture
The first build is meant to decide, not decorate.
The central question is whether pathological tau export can be separated from synaptic silencing, generic secretion shutdown, intracellular tau burden, or DNAJC5 loss-of-function liability.
Primary signal
Seed-competent extracellular tau and downstream recipient-cell seeding activity.
Cargo selectivity
Vesicle-normalized export, basal secretion counterscreens, and EV-fractionated tau.
On-target logic
DNAJC5 perturbation/rescue, kinetic precedence, and clearance controls.
Safety window
VAMP2/SNAP25 reserve, neuronal activity, neurite health, viability, and intracellular proteostasis.
Company thesis
PSP is the first validation beachhead. Cargo-export gatekeeping is the company thesis.
If validated, the same biology may inform broader age-related proteinopathies where proteostasis failure turns intracellular misfolded cargo into extracellular propagation risk.
Near-term milestones
Build donor/recipient tau-export assays.
Test DNAJC5/MAPS perturbation and rescue.
Separate cargo-selective export reduction from synaptic silencing.
Advance, redirect, or kill the lane with explicit criteria.
Boundary
Public materials are high-level and do not represent completed target validation, clinical utility, or medical guidance. IP has been filed; detailed claims and assay designs are shared selectively through diligence.
Origin
Developed through Lumenais/QARIN synthesis, then translated into a falsifiable wet-lab plan.
Computational synthesis
Literature, public datasets, and mechanistic contradictions were synthesized into a testable therapeutic hypothesis.
Diligence discipline
The program is structured around advance, redirect, or kill criteria rather than narrative confidence alone.
Contact
Seeking company-building, assay, and venture-creation partners.
Lumenais Bio is currently founder-led and preclinical. The next step is a focused validation build to determine whether this should become a financed therapeutics company.